Merck plans spending shift to boost business beyond Keytruda

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support of newer drugs and R&D.

By Jonathan Gardner • July 29, 2025

Novo cuts guidance, names new CEO as obesity drug challenges mount

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its competition with rival Eli Lilly.

By Ned Pagliarulo • July 29, 2025

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

GSK pays $500M to enter drugmaking alliance with Hengrui

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines and be worth $12 billion.

By Ben Fidler • July 28, 2025

Redefining commercial success in specialty lite with alternative channels

The optimal commercial strategy for specialty-lite brands – alternative channels to drive unparalleled commercial outcomes.

July 28, 2025

FDA delays approval decision for Bayer menopause therapy

The agency told Bayer it needs additional time to review the non-hormonal drug, called elinzanetant. Regulators in Canada and the U.K. have already cleared it for use.

By Delilah Alvarado • July 25, 2025

Bristol Myers shuffles its executive ranks with new CMO

AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit Hirawat, on Aug. 1.

By Gwendolyn Wu • July 25, 2025

Rocket lays off staff; Abivax capitalizes on immune drug data

The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck research deals.

By BioPharma Dive staff • July 24, 2025

AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trial

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells for myasthenia gravis.

By Ben Fidler • July 24, 2025

[Podcast] The Progress Profile: Alzheimer’s Research in Focus

Discover the latest breakthroughs in Alzheimer's research, diagnosis, and prevention in this expert-led podcast series.

By BioPharma Dive's studioID • July 24, 2025

Roche stops shipping Sarepta gene therapy in some countries outside US

The Swiss company, which markets Elevidys abroad, said it believes the benefit-risk balance to treatment remains positive in Duchenne patients who can still walk, however.

By Ned Pagliarulo • July 23, 2025

Replimune drug rejected by FDA; Omega raises $647M biotech fund

Analysts questioned whether the complete response letter Replimune received was evidence of changing approval standards at the FDA.

By BioPharma Dive staff • July 22, 2025

AstraZeneca grows US presence with $50B in spending plans

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and elsewhere, as well as R&D investment.

By Ned Pagliarulo • July 21, 2025

Apples to apples: Stelara biosimilars and the fight for market share

How will payers determine which Stelara biosimilar to add to their formularies?

By Samantha Ngan, Associate Manager, Market Research, MMIT and Andrew Rouff, Senior Consultant, Advisory Services, MMIT • July 21, 2025

Bristol Myers’ Reblozyl falls short in Phase 3; Blenrep voted down by FDA panel

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have become more difficult after the negative advisory committee vote.

By BioPharma Dive staff • July 18, 2025

Bristol Myers, Pfizer to offer Eliquis at a discount for some patients

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who aren’t insured or are willing to pay cash for their medications. 

By Ben Fidler • July 17, 2025

J&J absorbs Stelara, tariff hits to deliver beat-and-raise quarter

Quarterly pharmaceutical sales surpassed $15 billion for the first time as strong performance from J&J's cancer medicines offset slumping Stelara sales.

By Ned Pagliarulo • July 16, 2025

Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill into late-stage trials.

By BioPharma Dive staff • July 15, 2025

Takeda to seek approval of new kind of narcolepsy drug after study data

Positive late-stage study results position the company to file for clearance of what could be the first narcolepsy drug that targets orexin proteins. 

By Ben Fidler • July 14, 2025

From data to decisions: How pharma can move faster without sacrificing trust

Pharma's speed advantage depends on trust. Is your data foundation strong enough?

By Pankit Bhalodia, Partner at West Monroe Life Sciences • July 14, 2025

Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update

Current operations chief Renee Gala will succeed Bruce Cozadd at Jazz. Meanwhile, Nuclidium raised about $99 million to develop radiopharmaceuticals that involve copper isotopes.

By BioPharma Dive staff • July 11, 2025

AbbVie to pay $700M for trispecific drug from Ichnos Glenmark

The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and autoimmune conditions, too. 

By Kristin Jensen • July 10, 2025

Gilead signs lenacapavir access deal; Arvinas CEO to step down

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.

By BioPharma Dive staff • July 9, 2025

Trump says pharmaceutical, copper tariffs coming ‘very soon’

While Trump indicated drug levies would be set at a “very high” rate, he added that pharma firms would first be given time to bring manufacturing to the U.S.

By Philip Neuffer • July 8, 2025

Novartis gets approval of first malaria medicine for newborns

Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans to sell it “largely” on a not-for-profit basis.

By Delilah Alvarado • July 8, 2025

[Podcast] Trial Trailblazers: Behind clinical breakthroughs

Explore how innovative clinical trials are transforming treatments for children with rare diseases in this compelling podcast.

By BioPharma Dive's studioID • July 7, 2025